Stay updated with breaking news from Lukas Scheibler. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Rating) – Analysts at Oppenheimer reduced their FY2025 earnings per share (EPS) estimates for Apellis Pharmaceuticals in a research report issued to clients and investors on Thursday, April 21st. Oppenheimer analyst J. Kim now forecasts that the company will post earnings of $4.72 per share for the year, down […]
Wall Street brokerages expect that Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Rating) will post ($1.35) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Six analysts have provided estimates for Apellis Pharmaceuticals’ earnings. The lowest EPS estimate is ($1.69) and the highest is ($1.09). Apellis Pharmaceuticals reported earnings of ($2.32) per share in […]
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Rating) insider Lukas Scheibler sold 11,496 shares of the firm’s stock in a transaction dated Friday, April 1st. The shares were sold at an average price of $55.05, for a total transaction of $632,854.80. The sale was disclosed in a legal filing with the SEC, which can be accessed […]
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Rating) – Research analysts at Jefferies Financial Group lowered their FY2024 earnings per share estimates for Apellis Pharmaceuticals in a research note issued to investors on Tuesday, March 22nd. Jefferies Financial Group analyst C. Howerton now expects that the company will post earnings per share of $0.59 for the […]
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Rating) – Wedbush lifted their Q1 2022 earnings per share (EPS) estimates for Apellis Pharmaceuticals in a research report issued on Tuesday, March 1st. Wedbush analyst L. Chico now expects that the company will post earnings per share of ($1.09) for the quarter, up from their prior forecast of […]